TRIZIVIR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIZIVIR is an oral fixed-dose combination antiretroviral tablet approved in 2000 for HIV treatment. It combines multiple nucleoside reverse transcriptase inhibitors (NRTIs) in a single formulation to simplify patient dosing regimens. The drug works by inhibiting HIV reverse transcriptase, blocking viral replication in infected individuals.
$0.001BPart D
LOE ApproachingDeclining
Mature product nearing loss of exclusivity with minimal Part D utilization (618 claims in 2023), indicating a contracting team and limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
Started Aug 2006
17 enrolled
HIV
Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
Started Jun 2006
730 enrolled
HIV Infections
Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults
Started Jan 2005
152 enrolled
HIV Infections
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
Started Apr 2004
Infection, Human Immunodeficiency Virus IHIV Infection
FREE Study: Efficacy and Toxicity of Trizivir
Started Mar 2003
207 enrolled
HIV Infections
Worked on TRIZIVIR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.